Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
:GILD
GILD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.07 - $119.96
Previous CloseN/A
Volume1.95M
Average Volume (3M)10.91M
Market Cap
$129.19B
Enterprise Value$131.96B
Total Cash (Recent Filing)$936.88M
Total Debt (Recent Filing)$1.24B
Price to Earnings (P/E)270.9
Beta0.38
Next Earnings
Apr 24, 2025EPS Estimate
1.77Last Dividend Ex-Date
Mar 14, 2025Dividend Yield2.99%
Share Statistics
EPS (TTM)0.37
Shares Outstanding1,246,634,500
10 Day Avg. Volume11,311,788
30 Day Avg. Volume10,905,956
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.64
Price to Cash Flow (P/CF)11.20
P/FCF Ratio11.20
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.86
Enterprise Value/Ebitda29.76
Forecast
1Y Price Target
$115.28Price Target Upside11.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
---
Bulls Say, Bears Say
Bulls Say
Product LaunchLenacapavir is well positioned for a strong launch in PrEP and is expected to generate significant sales growth, with peak sales potentially reaching over $4 billion.
Stock RecommendationAnalysts maintain a positive outlook on Gilead Sciences, reiterating a Buy rating with a price target of $126.
Strategic PositioningThe company's oncology portfolio is seen as an important growth driver, with the CART franchise gaining scale and Trodelvy expanding into new indications.
Bears Say
Funding UncertaintyThe uncertainty surrounding potential funding cuts and more restrictive formularies for Medicaid necessitates careful monitoring of the situation.
Policy And Budget CutsProposed Medicaid cuts could significantly impact Gilead Sciences' earnings since Medicaid accounts for a substantial portion of the company's HIV revenues.
Revenue RisksThe underlying HIV business is expected to face a sequential decline in revenues due to seasonal inventory dynamics and IRA headwinds.
---
Ownership Overview
0.10% Insiders
31.43% Mutual Funds
22.54% Other Institutional Investors
19.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $62.07 and its highest was $119.96 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $129.19B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Apr 24, 2025 which is in 10 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Feb 11, 2025. The company reported $1.9 earnings per share for the quarter, beating the consensus estimate of $1.738 by $0.162.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $3.097 which represents an annual dividend yield of 2.99%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 1.77.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,246,634,500 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $1.9 in its last earnings report, beating expectations of $1.738. Following the earnings report the stock price went up 7.458%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in GILD
---
Gilead Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$115.28 (11.24% Upside)
$115.28 (11.24% Upside)
Blogger Sentiment
Bullish
GILD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 911.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.62%
12-Months-Change
Fundamentals
Return on Equity
2.28%
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
---
GILD Company Deck
---
GILD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong performance in key therapeutic areas, particularly in HIV and oncology, with successful product launches and promising pipeline developments. However, the company faces challenges from Medicare Part D reform, declining Veklury sales, and competitive pressures in cell therapies.Read More>---
GILD Revenue Breakdown
68.21% HIV
11.44% Oncology
10.51% Liver Disease
6.26% Veklury
3.59% Other
---
GILD Stock 12 Month Forecast
Average Price Target
$115.28
▲(11.24% Upside)
Technical Analysis
Best Analysts Covering GILD
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+18.13%
reiterated a buy rating 7 days ago
Copying Chris Schott's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +18.13% per trade.
---